Dr. Alice Shaw joined GRACE to discuss controlling brain metastases in patients with molecular driven advanced non-small cell lung cancer.
Nathan Pennell, MD, PhD, Director of Lung Cancer Medical Oncology at the Cleveland Clinic Taussig Cancer Center in Cleveland Ohio discusses new options in acquired resistance for ALK positive non-small cell lung cancer (NSCLC).
Our third video from the Targeted Therapies in Lung Cancer Patient Forum, filmed in Aurora Colorado on August 20, 2016, is the second part of the forum breakout session for ALK + patients and caregivers, featuring Dr. Shirish Gadgeel and patient moderator Linnea Olson.
On August 20, 2016, in collaboration with the University of Colorado Cancer Center, GRACE presented the Targeted Therapies in Lung Cancer Patient Forum in Aurora Colorado. We are happy to share the videos from this live and webcast forum. Our second video is the first part of the forum breakout session for ALK + patients and caregivers, featuring Dr. Shirish Gadgeel and patient moderator Linnea Olson.
On August 20, 2016, in collaboration with the University of Colorado Cancer Center, GRACE presented the Targeted Therapies in Lung Cancer Patient Forum in Aurora Colorado. We are happy to share the videos from this live and webcast forum. Our first video welcomes all to the event, and it was our extreme pleasure to have Chris Draft and Dr. Ross Camidge join us to start the day! This is followed by keynote topic "Does NED matter? Using “curative” surgery or radiation techniques to treat "incurable" advanced lung cancer," with Dr. Rob Meguid, and a panel discussion featuring Dr. Meguid, Dr. Chad Rusthoven, Dr. Ross Camidge, and chaired by Dr. H. Jack West.
Register Now for the Targeted Therapies Patient Forum
Hi Grace Members,
Grace is happy to present in partnership with the Swedish Cancer Institute " Local Therapies for Metastatic Lung Cancer Who, What, Why, When and How?" this Saturday, November 10, 2018 | 10:00 am– 1:00 pm Pacific time. This seminar will be available at no charge in person and as a live webinar.
This question is not for a specific patient, it is designed to understand how oncologists would approach this problem. There’s a 50 year old stage IIIb unresectable NSCLC patient with ALK positive FISH biopsy result. PD-L1 25%. ECOG 0-1. Should this patient be treated first line with Chemoradiation+Durvalumab or Alectinib? Would the recommendation be any different with EGFR mutation?
Dr. Alice Shaw joined GRACE to discuss the changing landscape of first-line treatment of ALK-positive advanced non-small cell lung cancer.
Dr. Alice Shaw joined GRACE to discuss patterns of resistance in ALK positive non small cell lung cancer.
Dr. Alice Shaw joined GRACE to discuss controlling brain metastases in patients with molecular driven advanced non-small cell lung cancer.
Nathan Pennell, MD, PhD, Director of Lung Cancer Medical Oncology at the Cleveland Clinic Taussig Cancer Center in Cleveland Ohio discusses new options in acquired resistance for ALK positive non-small cell lung cancer (NSCLC).
The FDA just approved a new therapy for the approximately 4% of patients with NSCLC who have the molecular marker known as an ALK rearrangement. The agent Zykadia (ceritinib), a "second generation" ALK inhibitor that is more effective than Xalkori (crizotinib) in lab models of ALK-positive NSCLC, and the new approval was for Zykadia as first line treatment for ALK-positive lung cancer, a setting where we have historically favored Xalkori since it was approved in 2011. .
Our third video from the Targeted Therapies in Lung Cancer Patient Forum, filmed in Aurora Colorado on August 20, 2016, is the second part of the forum breakout session for ALK + patients and caregivers, featuring Dr. Shirish Gadgeel and patient moderator Linnea Olson.
On August 20, 2016, in collaboration with the University of Colorado Cancer Center, GRACE presented the Targeted Therapies in Lung Cancer Patient Forum in Aurora Colorado. We are happy to share the videos from this live and webcast forum. Our second video is the first part of the forum breakout session for ALK + patients and caregivers, featuring Dr. Shirish Gadgeel and patient moderator Linnea Olson.
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.